New collaboration aims to advance drug delivery technology
INCHEON — Samsung Bioepis Co., Ltd. and its sister company, Epis NexLab Co., Ltd., have announced a research collaboration and licence agreement with G2GBIO, a developer of sustained-release formulations. This agreement aims to develop new long-acting therapies, including a semaglutide asset, leveraging G2GBIO’s proprietary microsphere technology. The collaboration marks a significant step forward in the biopharmaceutical industry, as it combines the expertise of leading companies in drug delivery and formulation.
According to Samsung Bioepis, they will receive exclusive rights to develop and commercialize two novel assets, with an option to licence additional assets. Epis NexLab will collaborate on developing the long-acting drug delivery platform. Financial details of the agreement remain undisclosed, but the strategic partnership is expected to accelerate the development of innovative therapies that address unmet medical needs.
Expanding Drug Delivery Capabilities
Kyung-Ah Kim, President and CEO of Samsung Bioepis, stated, “This agreement represents an important step in expanding our drug delivery capabilities and pipeline.” The partnership with G2GBIO and Epis NexLab aims to bring innovative therapies to patients while enhancing the delivery mechanisms of existing medications. The collaboration is anticipated to yield significant advancements in the treatment of chronic conditions, offering new hope for patients requiring long-term medication management.
This move comes as demand for advanced drug delivery systems continues to grow in the pharmaceutical industry, with companies seeking to improve patient outcomes through sustained-release and long-acting medications. The global market for these technologies is expanding rapidly, driven by the need for more effective and patient-friendly treatment options. As a result, collaborations like the one between Samsung Bioepis and G2GBIO are crucial in pushing the boundaries of what’s possible in drug development and delivery.
The collaboration is expected to pave the way for future innovations in drug delivery systems, potentially setting new standards in the industry. By focusing on long-acting therapies, the partnership underscores the growing importance of sustained-release formulations in enhancing patient compliance and overall health outcomes.
Source: newshub.medianet.com.au
Last updated: 1 April 2026, 10:31 am
